These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37077920)

  • 1. Epigenetic control of
    Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
    Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
    Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
    Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoplasmic reticulum glycoprotein quality control regulates CD1d assembly and CD1d-mediated antigen presentation.
    Kunte A; Zhang W; Paduraru C; Veerapen N; Cox LR; Besra GS; Cresswell P
    J Biol Chem; 2013 Jun; 288(23):16391-16402. PubMed ID: 23615906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
    Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
    Front Immunol; 2022; 13():955063. PubMed ID: 36248850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline deletion of β2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus.
    Singh RR; Yang JQ; Kim PJ; Halder RC
    Arthritis Res Ther; 2013 Mar; 15(2):R47. PubMed ID: 23531237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
    Tiper IV; Webb TJ
    Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
    Sade-Feldman M; Jiao YJ; Chen JH; Rooney MS; Barzily-Rokni M; Eliane JP; Bjorgaard SL; Hammond MR; Vitzthum H; Blackmon SM; Frederick DT; Hazar-Rethinam M; Nadres BA; Van Seventer EE; Shukla SA; Yizhak K; Ray JP; Rosebrock D; Livitz D; Adalsteinsson V; Getz G; Duncan LM; Li B; Corcoran RB; Lawrence DP; Stemmer-Rachamimov A; Boland GM; Landau DA; Flaherty KT; Sullivan RJ; Hacohen N
    Nat Commun; 2017 Oct; 8(1):1136. PubMed ID: 29070816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
    Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
    Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
    Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
    Front Immunol; 2022; 13():725679. PubMed ID: 35844619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.
    Hix LM; Shi YH; Brutkiewicz RR; Stein PL; Wang CR; Zhang M
    PLoS One; 2011; 6(6):e20702. PubMed ID: 21695190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9-Gene Signature Correlated With CD8
    Yan K; Lu Y; Yan Z; Wang Y
    Front Immunol; 2021; 12():622563. PubMed ID: 34220795
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
    Front Immunol; 2021; 12():672521. PubMed ID: 34177913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune-related role of beta-2-microglobulin in melanoma.
    Wang C; Wang Z; Yao T; Zhou J; Wang Z
    Front Oncol; 2022; 12():944722. PubMed ID: 36046045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.
    Sari G; Dhatchinamoorthy K; Orellano-Ariza L; Ferreira LM; Brehm MA; Rock K
    J Exp Clin Cancer Res; 2024 Oct; 43(1):276. PubMed ID: 39354629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.